ClinicalTrials.gg
RecruitingNCT06121297Updated Oct 6, 2026

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

A Phase 1/2 interventional study of CABA-201 and CABA-201 in Systemic Lupus Erythematosus and Lupus Nephritis, sponsored by Cabaletta Bio. Recruiting at 23 sites in 3 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Primary conditionLupus NephritisRegistry: Lupus Erythematosus, SystemicReclassifiedWhy we changed it
Registry
Lupus Erythematosus, Systemic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Nephritis
Why
  1. The study's listed conditions name Lupus Nephritis, a narrower term within Lupus Erythematosus, Systemic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cabaletta Bio · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Oct 6, 2026Eligibility revised3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Planned enrollment
63rd of 100
28 · median 50
Started
2024
with 15 others
Phase 1/2
12 of 114
6 open now
Primary completion
2029-12
later than 37 of 49 live
Registered
71st of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 63rd largest by planned enrollment of the 100 interventional ones that give a count, is one of 16 that started in 2024, is one of 12 in phase 1/2, reaches primary completion later than 37 of the 49 other live ones, and was the 71st registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Read the detailed description

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by autoantibody production and abnormal B cell function. SLE presents with fluctuating severity and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) (renal involvement) is a common severe manifestation of SLE, which can lead to significant morbidity and mortality. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, also called resecabtagene autoleucel, or "rese-cel". Rese-cel can be given to patients with either LN or SLE without renal involvement, in two separate parallel cohorts, who have active disease. Initially a single dose of CABA-201 in patients pretreated with a standard regimen including cyclophosphamide (CY) and fludarabine (FLU), will be evaluated. In addition, escalating doses of CABA-201 will be evaluated in patients without CY and FLU pretreatment.

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Lupus Nephritis

Browse trials for

Keywords

  • CABA-201
  • Autoimmune Disease
  • Anti-CD19 CAR-T therapy
  • Cellular Therapy
  • Systemic Lupus Erythematosus
  • Lupus Nephritis
04

In context

Lupus Nephritis Reclassified

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

This study's planned enrollment of 28 is below the median of 48 across 243 interventional studies indexed under Lupus Nephritis.

Browse Lupus Nephritis studies →

Lead sponsor

Cabaletta Bio is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Compared within Lupus Nephritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lupus Erythematosus, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 and ≤65 (Adults) or Age ≥12 to \<18 years (Adolescents)
  • A clinical diagnosis of SLE, based on the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE.
  • Positive antinuclear antibody (ANA) titer or anti-dsDNA antibody at screening.
  • For LN subjects only, active, -proven LN class III or IV, with or without the presence of class V, according to 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria
  • For non-renal SLE subjects only: Active, moderate to severe SLE

Exclusion criteria

Exclusion Criteria:

  • to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the product or with the study procedures
  • For LN subjects only: The presence of kidney disease other than active lupus nephritis
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    CABA-201 with FLU/CY Preconditioning

    LN Cohort: Infusion of CABA-201 with preconditioning in subjects with LN Non-renal SLE Cohort: Infusion of CABA-201 with preconditioning in subjects with non-renal SLE who do not meet criteria for inclusion in the LN cohort Expansion Cohort: Infusion of CABA-201 with preconditioning in subjects with LN and SLE

    Biological: CABA-201

  • Experimental
    CABA-201, No Preconditioning

    Infusion of CABA-201 with no preconditioning in subjects with LN and non-renal SLE

    Biological: CABA-201

Interventions

  • BiologicalCABA-201

    Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

  • BiologicalCABA-201

    Single intravenous infusion of CABA-201 at escalating dose levels without preconditioning

07

What researchers measure

Primary outcomes

  1. To evaluate incidence of adverse events

    Time frame: Up to 28 days after CABA-201 infusion

Secondary outcomes

  1. To evaluate adverse events and laboratory abnormalities

    Incidence and severity of AEs, including changes in laboratory values and vital signs

    Time frame: Up to 156 weeks

  2. To characterize the pharmacodynamics (PD)

    Levels of B cells in the blood

    Time frame: Up to 156 weeks

  3. To characterize the pharmacokinetics (PK)

    Levels of CABA-201-positive T cells in the blood

    Time frame: Up to 156 weeks

  4. To evaluate disease related biomarkers

    Levels of C3, C4, and CH50 in serum

    Time frame: Up to 156 weeks

  5. To evaluate disease related biomarkers

    Levels of anti-double stranded DNA (anti-dsDNA) in serum

    Time frame: Up to 156 Weeks

  6. To evaluate efficacy

    Complete renal response rates (in subjects with LN)

    Time frame: Up to 156 Weeks

  7. To evaluate efficacy

    SRI-4, BICLA and DORIS remission and LLDAS response rates

    Time frame: Up to 156 weeks

08

Study locations

20 of 23 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Dec 2029, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 7, 2023
StartActual
Feb 16, 2024
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (3 United States)
  • The University of Chicago Medical Center - Accepting Adult and Adolescent Patients · Chicago, United States
  • Boston Children's Hospital - Accepting Young Adult and Adolescent Patients · Boston, United States
  • Children's Hospital of Philadelphia - Accepting Young Adult and Adolescent Patients · Philadelphia, United States
Show 3 removed
  • The University of Chicago Medical Center · Chicago, United States
  • Boston Children's Hospital · Boston, United States
  • Children's Hospital of Philadelphia · Philadelphia, United States
Oct 6, 2026
Eligibility
Minimum age 18 Years→12 Years; 2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Age ≥18 and ≤65Now Age ≥18 and ≤65 (Adults) or Age ≥12 to <18 years (Adolescents)
  • EditedA clinical diagnosis of SLE, based on the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for adult SLE.
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 United States)
    • The University of Chicago Medical Center - Accepting Adult and Adolescent Patients · Chicago, United States
    • Boston Children's Hospital - Accepting Young Adult and Adolescent Patients · Boston, United States
    • Children's Hospital of Philadelphia - Accepting Young Adult and Adolescent Patients · Philadelphia, United States
    Show 3 removed
    • The University of Chicago Medical Center · Chicago, United States
    • Boston Children's Hospital · Boston, United States
    • Children's Hospital of Philadelphia · Philadelphia, United States
    Eligibility Minimum age 18 Years→12 Years; 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Age ≥18 and ≤65Now Age ≥18 and ≤65 (Adults) or Age ≥12 to <18 years (Adolescents)
    • EditedA clinical diagnosis of SLE, based on the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for adult SLE.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06121297
Lead sponsor
Cabaletta Bio
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Feb 16, 2024
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Cabaletta Bio
Contact
clinicaltrials@cabalettabio.com
267 759 3100 ext. 4444
Medical Director
study chair · Cabaletta Bio

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD19 CAR-T Cells CABA-201

Start the discussion